Skip to Main Content
Creatv Bio
  • Home
  • About
    • Company
    • Management Team
    • News
  • Assay
  • BioPharma Services
  • Publications
    • All Publications
    • Journals
    • Presentations
  • Training Videos
  • Contact
Poster & Oral

Presentations

A collection of Creatv Bio’s posters and oral presentations shared at research conferences.

  • All Topics
  • Blood-based Tumor Markers
  • Cancer Associated Macrophage-like Cells (CAMLs)
  • Cancer Screening
  • Clinical Trials and Biopharma Services
  • Companion/Complementary Diagnostics
  • Companion Diagnostics for PD-L1
  • Detection of Recurrence
  • Determination of Cancer Aggressiveness
  • Determination of Response to Therapy
  • Monitoring Change of PD-L1 Expression
  • Residual Disease
  • Sequential Monitoring of Tumor Marker Status During Therapy
  • Treatment Modalities
  • Tumor Macrophage Hybrid Cells (TMHCs)
  • Tumor Types We Have Tested
ASCO 2025 Poster Presentation

Monitoring populations of tumor-macrophage fusion cells in blood prognosticates PFS and OS in pan-metastatic cancers over 2 years

AACR 2023 Poster Presentation

Peripheral blood biomarkers in Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer

SABCS 2023 Poster Presentation

Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer

AACR 2022 Poster Presentation

Changes in Circulating Tumor Associated Cells Predicts Progression Free and Overall Survival in Metastatic TNBC Patients after Induction with the Anti-CCR5 Drug Leronlimab

SABCS 2022 Poster Presentation

Decreases in Circulating Tumor Associated Cells Predict PFS and OS in a Pooled Analysis of Phase I Clinical Trials Using SV-BR-1-GM Therapy with or without Immune Check-Point Inhibitors in Metastatic Breast Cancer Patient

ASCO 2022 Poster Presentation

Monitoring engorgement of phagocytic circulating stromal cells during chemo-radiotherapy induction predicts survival in unresectable stage 2/3 NSCLC

ASCO 2022 Poster Presentation

Tracking changes in circulating stromal cells and circulating tumor cells predicts responsiveness of new line induction in metastatic breast cancer after 1 cycle of therapy

AACR 2019 Poster Presentation

CAMLs are a circulating stromal cell subpopulation that accurately predicts resistance and progression in treatment naïve lung cancer patients receiving definitive radiotherapy

Tri-Con 2019 Poster Presentation

Changes in the type of circulating cancer associated macrophage-like cells during and after radiation therapy is associated with progression in thoracic cancers

Keystone Symposium Conference Poster Presentation

SV-BR-1-GM, a breast cancer cell line with features of dendritic cells, induces tumor regression in HLA matched Stage IV breast cancer patients

ASCO 2018 Poster Presentation

Combining circulating tumor cells (CTCs) and circulating cancer associated macrophage - like cells (CAMLs) for accurately predicting responsiveness of new line therapies in late stage cancers

AVI 2015 Poster Presentation

A Cell Based Liquid Biopsy for Immunotherapeutic Drug Development

ASCO 2015 Poster Presentation

Cancer associated macrophage-like cells correlate with systemic therapy and pathological stage in numerous malignancies

© 2026 Creatv Bio, a Division of Creatv MicroTech, Inc.
Creatv Bio on LinkedIn Creatv Bio on Facebook
Privacy Policy Terms of Use Login

Research Use Only (RUO) Disclaimer

The Creatv Bio website and the information provided through this website, including text, outcomes, charts and graphics, are intended solely for Research Use Only (RUO) and are intended for qualified research, pharmaceutical, biotechnology, and academic research organizations. They should not be considered medical advice and are not intended for clinical diagnostic use, patient testing, patient management, or use by patients or healthcare professionals for making medical decisions.

The products, services, and information described on this website have not been, evaluated, cleared, approved, or authorized by the U.S. Food and Drug Administration (FDA) for clinical diagnostic use and are not intended to be used for diagnosis, treatment, prevention, or monitoring of disease. Reliance on any data or information provided on this website is strictly at your own risk.

Creatv Bio’s RUO activities are separate from clinical laboratory testing performed under CLIA. Nothing on this website should be interpreted as representing that the RUO products or services constitute CLIA-certified patient testing.

If you are a patient or healthcare professional seeking clinical laboratory testing, please visit the LifeTracDx website.